Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Botta

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
European Annals of Allergy and Clinical Immunology|October 30, 2025
Small airway dysfunction in asthma: concordance and discordance between spirometry and oscillometry in real-lifeA Botta, C P Ratti, A Chiei Gallo, et al.
American Journal of Cancer Research|August 10, 2023
Challenges and prospects of CSF1R targeting for advanced malignanciesAnn Moeller, Razelle Kurzrock, Gregory P Botta, et al.
The Oncologist|December 23, 2022
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell CarcinomaGeorges Azzi, Mehrad Tavallai, Vasily N Aushev, et al.
Nature Communications|March 22, 2021
Tumor-penetrating therapy for β5 integrin-rich pancreas cancerTatiana Hurtado de Mendoza, Evangeline S Mose, Gregory P Botta, et al.
ESMO Open|March 19, 2024
Viewing the immune checkpoint VISTA: landscape and outcomes across cancersD Nishizaki, R Kurzrock, H Miyashita, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational statusE B Faber, Y Baca, J Xiu, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cellsGregory P Botta, Joseph Chao, Hong Ma, et al.
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
European Annals of Allergy and Clinical Immunology|October 30, 2025
Small airway dysfunction in asthma: concordance and discordance between spirometry and oscillometry in real-lifeA Botta, C P Ratti, A Chiei Gallo, et al.
American Journal of Cancer Research|August 10, 2023
Challenges and prospects of CSF1R targeting for advanced malignanciesAnn Moeller, Razelle Kurzrock, Gregory P Botta, et al.
The Oncologist|December 23, 2022
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell CarcinomaGeorges Azzi, Mehrad Tavallai, Vasily N Aushev, et al.
Nature Communications|March 22, 2021
Tumor-penetrating therapy for β5 integrin-rich pancreas cancerTatiana Hurtado de Mendoza, Evangeline S Mose, Gregory P Botta, et al.
ESMO Open|March 19, 2024
Viewing the immune checkpoint VISTA: landscape and outcomes across cancersD Nishizaki, R Kurzrock, H Miyashita, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational statusE B Faber, Y Baca, J Xiu, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cellsGregory P Botta, Joseph Chao, Hong Ma, et al.
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Pageof 4